Background. Most new tuberculosis vaccines will be administered as a booster to subjects primed with bacille Calmette-Guérin (BCG) during childhood.
in which tuberculosis is endemic administer bacille Calmette-Guérin (BCG) at birth, many candidate tuberculosis vaccines will first be tested as booster vaccines in subjects who were primed with BCG at birth [6] . Persons with HIV infection are at the highest risk of morbidity and mortality from tuberculosis and represent a priority for the development of improved tuberculosis vaccine strategies [7] . Baseline cellular and humoral immune responses to mycobacteria after BCG vaccination have been characterized in HIV-negative individuals [8, 9] but not in a large cohort of HIVinfected adults with a history of childhood BCG immunization, to evaluate their suitability for boosting. Here, we present data on skin test results and in vivo responses to mycobacterial antigens among HIV-infected subjects entering a phase 3 tuberculosis booster vaccine trial in Tanzania (the DARDAR Study). 
METHODS
Study subjects and protocol. The DARDAR Study is a phase 3 trial of a prime-boost vaccine strategy for the prevention of HIV-associated tuberculosis (the prime is BCG during childhood; the boost is multiple-dose whole-cell inactivated mycobacterial vaccine) that is being conducted in Dar es Salaam, Tanzania [10] . Ambulatory HIV-infected subjects у18 years old are referred from voluntary HIV counseling and testing centers in Dar es Salaam or by other study subjects. All subjects are screened via a standardized interview (which includes history of treatment for active tuberculosis), physical examination, measurement of CD4 cell count, and single-view chest radiography. Eligible subjects who provide informed consent are enrolled if they have 2 positive ELISA antibody test results for HIV, a CD4 cell count у200 cells/mm 3 , a BCG scar, and no evidence of active tuberculosis. Subjects with CD4 cell counts у200 cells/mm 3 who are potentially eligible for the study are further evaluated via 3 expectorated sputum samples collected for acid-fast bacilli smear and culture and a single mycobacterial blood culture. All subjects undergo baseline phlebotomy for assessment of mycobacterial immune responses and then have 2 intradermal skin tests performed: 0.1-mL tuberculin (RT-23; State Serum Institute, Denmark) and 0.1-mL Mycobacterium avium sensitin (MAS; State Serum Institute). Skin tests are read as millimeters of induration at 48-72 h, and reactions у5 mm are considered to be positive. The human-experimentation guidelines of the US Department of Health and Human Services, as well as those of the Research Ethics Committee of the Muhumbili University College of Health Sciences, were followed in the conduct of this research. This study is registered through the US National Institutes of Health (NCT00052195).
Laboratory methods. Serum samples were tested by 2 different HIV ELISA methods. The Vironostika HIV Uni-Form II Ag/Ab test (bioMérieux) was used first, with reactive samples being retested by the Vironostika HIV Uni-Form II Plus O test (bioMérieux). Only samples that were reactive in both tests were accepted as being positive. Blood was collected in EDTA tubes for enumeration of CD4 cells by use of a FACSCount machine (Becton Dickinson) after staining with monoclonal antibodies [11] .
Lymphocyte proliferation assays (LPAs) were done on freshly isolated peripheral-blood mononuclear cells by a standard [ 3 H]-thymidine incorporation method, with a 5-day stimulation with either medium alone, 2 mg/mL M. vaccae sonicate (MVS), 1 mg/mL M. tuberculosis antigen 85 (Ag85), 2 mg/mL M. tuberculosis early secreted antigen (ESAT)-6, or 1 mg/mL M. tuberculosis whole-cell lysate (WCL). Results were expressed as a proliferation index (PI; counts per minute for the antigenstimulated cells divided by that for the unstimulated cells) and a PI у3 was considered to be positive. LPAs were considered to be valid if the positive control (2.5 mg/mL phytohemagglutinin) or one of the experimental antigens had a PI у3, there was no spillover between wells, and the counts per minute for the unstimulated cells was !5000.
Interferon (IFN)-g levels in cell culture supernatants after a 5-day stimulation with the same antigens used in the LPAs were determined by ELISA. Levels of antibody to M. tuberculosis lipoarabinomannin (LAM) were measured by standard ELISA. Serum from an M. tuberculosis-experienced individual, aliquotted into small samples and diluted 1:10 in 5% goat serum in PBS, was used as a positive control, and the color reaction in each assay was allowed to develop until the OD of the positive control reached 2.0. A pool of serum samples from tuberculosis-naive individuals was used as a negative control. Positive results for the IFN-g supernatant and LAM antibody ELISAs were defined as у3 SDs above the mean.
Statistical analysis. Standard descriptive statistical methods were used to characterize baseline immunological responses to mycobacterial antigens. Comparisons between groups were done using 2-sided t tests; was considered to be statis-P ! .05 tically significant. Data analysis was undertaken on Stata software (version 8; StataCorp).
RESULTS
Characteristics of the study subjects are shown in table 1. All subjects were HIV positive, had BCG scars, and had CD4 cell counts у200 cells/mm 3 . Of the 888 subjects enrolled in the study to date, baseline LPA results were available for 549, IFNg results were available for 742, and paired results were available for 454. LAM results were available for all 888 subjects. Prior treatment for tuberculosis was reported by 9% of the subjects. Skin test results are summarized in table 2. Approximately onethird of the subjects had positive PPD skin test results, with equivalent rates in patients with CD4 cell counts !500 and у500 cells/mm 3 . Figure 1 shows the percentage of subjects who had detectable immune responses to mycobacterial antigens on in vivo testing. Fully 94% of the subjects had detectable mycobacterial immune responses by any assay and 76% had detectable immune responses by LPA or IFN-g ELISA, whereas only 34% had a positive PPD skin test result. Table 3 provides data on in vivo immune responses to mycobacterial antigens. Responses were highest to WCL, with recognition by 58% of the subjects by LPA and by 38% of the subjects by IFN-g ELISA. Responses to the tuberculosis-specific antigen ESAT-6 were lower, at 21% by LPA and 12% by IFN-g ELISA. Differences in response rates by CD4 cell count were more pronounced for the IFN-g ELISA, by which responses were seen more frequently in the subjects with CD4 cell counts у500 cells/mm 3 . However, LPA responses to ESAT-6 were more pronounced in the lower CD4 cell count stratum. Levels of antibody to the nonspecific mycobacterial antigen LAM were similar in subjects with CD4 cell counts !500 and у500 cells/mm 3 . Table 4 shows that 94% of all HIVinfected subjects responded to either an in vivo or in vitro assay of mycobacterial immune responses. Table 5 shows that detectable cellular, but not humoral, immune responses to Ag85, ESAT-6, and WCL were more frequent in the subjects with a positive PPD skin test result than in those with a negative result. Proliferative responses to MVS were slightly more frequent in the subjects with a positive PPD result, whereas the frequency of IFN-g responses was not different between the 2 groups.
The 45 subjects without detectable immune responses to mycobacteria by skin test, LPA, IFN-g ELISA, or LAM antibody ELISA had similar ages (median, 31 vs. 33 years;
) and P p .088 We used 4 different methods to detect mycobacterial immune responses and assayed reactions to both specific and nonspecific mycobacterial antigens. In vivo intradermal skin testing with tuberculin, a nonspecific preparation of proteins derived from M. tuberculosis, detected delayed-type hypersensitivity (DTH) reactions in only 34% of subjects. Notably, the proportion of subjects with positive results for tuberculin skin testing was not different by CD4 cell count strata (!500 and у500 cells/mm 3 ). In vitro testing detected a higher proportion of mycobacterial immune responses than did in vivo testing. The most widely recognized antigen was WCL. As with tuberculin, it is likely that reactions to this reagent may have been due to latent tuberculosis, prior infection with nontuberculous mycobacteria, immunization with BCG [12] , or some combination thereof. Proliferative responses to the M. tuberculosis antigen ESAT-6 were present in 35% of the subjects with proliferative responses to WCL, whereas 26% of the subjects with IFN-g responses to WCL also had detectable responses to ESAT-6. These data reflect the minimum proportion of subjects whose mycobacterial immune responses are the result of prior infection with or disease due to M. tuberculosis [13] .
Although IFN-g responses were more common in the subjects with CD4 cell counts у500 cells/mm 3 , LPA responses to ESAT-6 were notably higher in the lower CD4 cell count stratum. This is an unexpected result, because proliferative responses to alloantigens typically wane during the progression of HIV infection [14] . We postulate that lower CD4 cell counts may correlate with a longer time at risk for HIV-related recrudescent tuberculosis and a consequent increase in tuberculosisspecific T cell proliferation, and we will continue to assess this pattern as enrollment continues.
The results of IFN-g ELISAs and LPAs did not correlate perfectly. One major reason for this observation is the fact that the 13 SD threshold used to consider an IFN-g result to be positive in a population highly exposed to mycobacteria is more stringent than the PI used in the LPAs. It is likely that a greater proportion of IFN-g responses would have been considered positive if the cutoff used was based instead on the mean response in an unexposed population. Beyond this, the discordant results from IFN-g and LPA testing may in part reflect the complex immune response to mycobacteria, which may not always involve coordinated and simultaneous lymphoproliferative and cytokine responses. Last, some part of this discordance is likely attributable to HIV infection, which clearly alters immune responses to mycobacteria, as supported by the higher frequency of IFN-g responses in the higher CD4 cell count stratum.
Our findings have several implications for the interpretation of previous BCG studies and for the design and interpretation of newer studies of prime-boost tuberculosis immunization strategies. Most trials of BCG in mycobacteria-naive infants and newborns have shown efficacy rates of 75%-80% [15] . Importantly, BCG trials in older children and adults were designed to exclude subjects with preexisting mycobacterial immune responses but relied on in vivo DTH skin testing to detect such immune responses. However, we have shown that, in an HIV-infected population, DTH skin testing is much less sensitive than combined contemporary in vivo or ex vivo assays of immune response to mycobacteria. These data raise the possibility that prior studies of BCG efficacy in HIV-uninfected subjects designated a significant fraction of subjects as being mycobacteria naive when more-contemporary assays would instead have demonstrated detectable mycobacterial immunity. This possibility, which warrants additional investigation, could result in an artifactual diminution of the apparent efficacy of BCG in these populations, because BCG vaccination may not have been undertaken in an entirely mycobacterianaive population.
Studies in HIV-negative subjects who received BCG during childhood have shown demonstrable in vivo responses to mycobacterial antigens during adulthood [8, 9] . In vitro cytokine secretion to tuberculin PPD has also been reported in as many as 49% of HIV-positive adults with scars from childhood BCG vaccination [16] . The present study is the first to examine both in vivo and in vitro responses to multiple mycobacterial antigens in HIV-positive adults who received BCG during childhood and is the first to show that such responses are detectable in almost all subjects. Even when our analysis is restricted to LPA and IFN-g responses, which reflect critical cellular immunity to mycobacteria, the present data demonstrate that the great majority of HIV-infected adults in Tanzania have primed mycobacterial immunity.
Because tuberculosis-specific cellular immune responses are impaired in BCG-vaccinated HIV-infected adults [17] , higher rates of prior mycobacterial immune responses would be likely in adults without HIV infection from the same area. The 6% of subjects without detectable responses to mycobacterial antigens by any assay are demographically similar to the subjects with immune responses to mycobacteria. These 6% may represent a mix of subjects with HLA types who did not optimally present the antigens used in this study, subjects with HIV-induced functional impairment of immune responses, and adults who remain truly mycobacteria naive. More-sensitive assays (such as the enzyme-linked immunospot assay) and the use of additional antigens (e.g., culture filtrate protein 10) may have shown a greater prevalence of detectable mycobacteria-specific immune responses in subjects with exposure to mycobacteria.
We demonstrated a low baseline frequency of responses to MVS. This shows that, although HIV-infected subjects in Tanzania have a likelihood of prior exposure to mycobacterial antigens, preexisting immune responses to M. vaccae are uncommon. This means that detection of vaccine-induced responses to M. vaccae will be possible even in a mycobacteria-experienced population.
In summary, HIV-infected adults in Tanzania who had received childhood BCG vaccination were highly likely to demonstrate detectable immune responses to mycobacteria and, thus, are effectively primed for booster vaccination with MVS.
